An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World Practice

Rheumatoid Arthritis Clinical Trial

— UPDATE  

Official title:

Impact of UPaDacitinib Treatment on inflAmmaTion, AchiEvement of Treatment Targets and Health-related Quality of Life, Work Ability and Healthcare Resource Utilization in Moderate to Severe Rheumatoid Arthritis Patients in Hungarian Real-world Practice

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05327920
• Other study ID #: P22-125
• Status: Completed
• Start date: April 20, 2022
• Est. completion date: April 22, 2024

Study information

• Verified date: May 2024
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. Despite the range of treatment options for RA steadily increasing, many patients remain sub-optimally managed, with sustained clinical remission rarely achieved. This study will assess the impact of upadacitinib treatment on achievement of remission and low disease activity in moderate to severe RA Hungarian patients in the real-world setting.

Upadacitinib is an approved drug for the treatment of adults with moderately to severely active RA. Adult participants with moderate-to-severe RA will be enrolled. Around 90 participants who are prescribed upadacitinib in routine clinical practice will be enrolled in the study in approximately 8 sites in Hungary.

Participants will receive upadacitinib as prescribed by the physician and will be followed for approximately 12 months.

There will be no additional burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic and only data which are routinely collected during a regular visit will be utilized for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 93
• Est. completion date: April 22, 2024
• Est. primary completion date: April 22, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of moderate to severe active rheumatoid arthritis (RA) upon judgment of the treating physician.

• Upadacitinib prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies and upadacitinib treatment was started within 1 week before the enrollment.

• Physician decision on participant treatment with upadacitinib must have been reached prior to and independently of recruitment in the study.

Exclusion Criteria:

• Participants who cannot be treated with upadacitinib as per SmPC or local prescription criteria.

• Prior treatment course with upadacitinib or the current upadacitinib treatment was started more than 1 week prior to enrollment.

• Participant currently participating in any interventional study.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Locations

Country	Name	City	State
Hungary	Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz /ID# 234204	Budapest
Hungary	Debreceni Egyetem-Klinikai Kozpont /ID# 246156	Debrecen	Hajdu-Bihar
Hungary	Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz /ID# 234201	Gyor	Gyor-Moson-Sopron
Hungary	Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz /ID# 239231	Gyula
Hungary	Kistarcsai Flor Ferenc Korhaz /ID# 234202	Kistarcsa
Hungary	BAZ Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 246158	Miskolc
Hungary	Szegedi Tudományegyetem /ID# 244364	Szeged
Hungary	MÁV Kórház /ID# 246157	Szolnok

Sponsors (1)

Lead Sponsor	Collaborator
AbbVie

Country where clinical trial is conducted

Hungary, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Achieving 28-Joint Disease Activity Score (DAS28) C-reactive protein (CRP) Remission following initiation of treatment with Upadacitinib	The DAS28 CRP is a composite measure of a patient's level of disease activity at a given time. The score ranges from 0-9.4 with a higher score correlating to higher disease activity. Remission is defined as a DAS28 CRP <2.6.	6 Months
Secondary	Percentage of Participants Achieving DAS28 CRP Remission following Initiation of Treatment with Upadacitinib	The DAS28 CRP is a composite measure of a patient's level of disease activity at a given time. The score ranges from 0-9.4 with a higher score correlating to higher disease activity. Remission is defined as a DAS28 CRP <2.6.	Up to 12 Months
Secondary	Percentage of Participants Achieving DAS28 CRP Remission at month 6 and maintain it in all subsequent visits	The DAS28 CRP is a composite measure of a patient's level of disease activity at a given time. The score ranges from 0-9.4 with a higher score correlating to higher disease activity. Remission is defined as a DAS28 CRP <2.6.	Up to 12 Months
Secondary	Percentage of Participants Achieving DAS28 CRP Low Disease Activity (LDA) following Initiation of Treatment with Upadacitinib	The DAS28 CRP is a composite measure of a patient's level of disease activity at a given time. The score ranges from 0-9.4 with a higher score correlating to higher disease activity. Low disease activity is defined as DAS28 CRP <=3.2.	Up to 12 Months
Secondary	Percentage of Participants Achieving DAS28 CRP Low Disease Activity at month 6 and maintain it in all subsequent visits	The DAS28 CRP is a composite measure of a patient's level of disease activity at a given time. The score ranges from 0-9.4 with a higher score correlating to higher disease activity. Low disease activity is defined as DAS28 CRP <=3.2.	Up to 12 Months
Secondary	Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score	The HAQ-DI assesses physical function in RA. The HAQ-DI score is the average of the highest score in each of eight categories. The total score is between 0-3.0, in 0.125 increments. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment	Up to 12 Months
Secondary	Change from Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score	The FACIT-Fatigue Scale measures an individual's level of fatigue during their usual daily activities over the past week on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The score range for FACIT-Fatigue is between 0 and 52. A score of less than 30 indicates severe fatigue. The higher the score, the better the quality of life.	Up to 12 Months
Secondary	Change from Baseline in EQ-5D-5L Score	The EQ-5D-5L comprises of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The respondent selects one of three different levels of problem severity. The levels are none, moderate and severe/extreme (coded 1 through 3, respectively).	Up to 12 Months
Secondary	Change from Baseline in Morning Stiffness Visual Analogue Scale (VAS) Score	The participant's level of morning stiffness in the past 7 days will be measured using a VAS. VAS scores range from 0 to 100 points with a higher score indicating severity of morning stiffness.	Up to 12 months
Secondary	Change from Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM) Score	TSQM scores have a range of 0 to 100, with higher scores indicating higher satisfaction. The 14 items of the TSQM cover four domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction.	Up to 12 Months
Secondary	Change from Baseline in Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis (WPAI-RA) Score	The WPAI-RA measures the impact of health problems on presenteeism, absenteeism, total work productivity impairment, total activity impairment using a 0 to 10 VAS.	Up to 12 Months
Secondary	Health Resource Utilization (HRU) Questionnaire - Difference in the Number of Hospital Inpatient Days	Difference in the number of hospital inpatient days during 12 months of upadacitinib therapy and 12 months preceding the introduction of upadacitinib therapy.	12 months prior to month 0 (baseline) and 12 months prior to month 12
Secondary	HRU Questionnaire - Difference in the Number of Hospitalizations	Difference in the number of hospital inpatient days during 12 months of upadacitinib therapy and 12 months preceding the introduction of upadacitinib therapy.	12 months prior to month 0 (baseline) and 12 months prior to month 12
Secondary	HRU Questionnaire - Difference in the Number of Sick Leave Days (in employed subjects only)	Difference in the number of hospital inpatient days during 12 months of upadacitinib therapy and 12 months preceding the introduction of upadacitinib therapy.	12 months prior to month 0 (baseline) and 12 months prior to month 12
Secondary	HRU Questionnaire - Difference in the Number of Sick Leaves (in employed subjects only)	Difference in the number of sick leaves during 12 months of upadacitinib therapy and 12 months preceding the introduction of upadacitinib therapy.	12 months prior to month 0 (baseline) and 12 months prior to month 12
Secondary	HRU Questionnaire - Difference in the Number of Outpatient Visits to Each Kind of Health Care Provider	Difference in the number of outpatient visits to each kind of health care provider which includes general practitioner, rheumatologist, other specialists (ophthalmologist, gastroenterologist, dermatologist, physiatrist), physiotherapist and rheumatology nurses during 12 months of upadacitinib therapy and 12 months preceding the introduction of upadacitinib therapy.	12 months prior to month 0 (baseline) and 12 months prior to month 12
Secondary	Percentage of Participants remaining on Upadacitinib treatment	Percentage of participants remaining on upadacitinib up to 12 months post initiation.	Up to 12 Months

External Links

•   Related Info